Dr. Craig Dees, CEO of Provectus - Promising Results in Phase II for Melanoma - June 5, 2013

Please join us - NevBio evening event:

Dr. Craig Dees, CEO of Provectus Pharmaceuticals, Inc.

"Promising Results with Melanoma Lesions in Phase II Trial of 80 subjects"

Wednesday, June 5th, 5:30 pm

Panevino Restaurant (New location)

RSVP here. $10 (Students, researchers & anyone involved in cancer - no charge)

Provectus Pharmaceuticals, Inc.is an oncology and dermatology biopharmaceutical company which is conducting Phase 2 trials of its drug, PV-10 as a treatment for metastic melanoma.

PV-10 selectively destroys cancer cells without harming surrounding healthy tissue. As reported in Practical Dermatology, the phase II open label, single-arm trial, 80 subjects with AJCC Stage III/ IV melanoma received treatment for one to 10 target lesions and up to 10 non-target lesions; at least one target lesion had to have biopsy confirmation of the diagnosis. Target lesions were >0.2cm diameter. Intralesional dosing was provided at 50 percent of the calculated lesion volume. Retreatment was allowed at weeks 8, 12, or 16, and all subjects were followed for 52 weeks.

According to final outcome data provided by Provectus, a Complete Response (CR: complete disappearance of the tumor) of PV-10 injected lesions was achieved in 26 percent of subjects, Partial Response (PR: at least a 30 percent reduction in tumor volume) was seen in 25 percent of subjects, and Stable Disease (SD: less than 20 percent increase in tumor volume) was seen in 18 percent of subjects. Less than one-third (31 percent) of subjects experienced Disease Progression (DP: 20 percent or greater increase in tumor volume).

Dr. Craig Dees & Provectus have had impressive results from their Phase 2 study and are preparing for Phase 3.

We want to thank Dominic Rodrigues for generously supporting the effort to have Dr. Dees speak in Las Vegas.

There's a lot more to the story of Dr. Dees & Provectus. I hope you can join us on Wednesday, June 5th.